Sandra E. Kurtin, PhD, ANP-C, AOCN, on Treating CLL in the Community Setting: Early Discontinuation of First-Line Ibrutinib

Sandra E. Kurtin, PhD, ANP-C, AOCN, of the University of Arizona Cancer Center, discusses the findings of a retrospective study that assessed the use of first-line ibrutinib for chronic lymphocytic leukemia in the United States. Although the agent was increasingly used in this setting, early discontinuation was more common than reported, suggesting clinical decision support tools and care delivery approaches should be explored (Abstract 797).